Compare Fortinet Inc (FTNT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Tango Therapeutics Inc. — how do they compare? Fortinet Inc trades at $182.97 (market cap $139.96B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Fortinet Inc is far larger — about 37.3× Tango Therapeutics Inc.'s market cap, and Fortinet Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and Tango Therapeutics Inc. for 0 Days on average.
| FTNT | TNGX | |
|---|---|---|
Market Cap | $139.96B | $3.75B |
Volume | 2,774,680 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $194.75 | $32.90 |
52-Week Low | $75.23 | $7.50 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $136.39B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $184.05, down 4.61% today, but maintains a bullish technical trend with strong fundamental performance. The company reported revenue of $6.80B in 2025 with a net income margin of 28.17%, and has consistently beaten earnings expectations in recent quarters. Recent news highlights its leadership in AI-driven cybersecurity and robust platform demand, with the stock nearing its 52-week high.
The outlook remains positive given strong earnings beats and raised 2026 guidance, though high valuation ratios (P/E 67.41) and competitive pressures pose risks. Analyst consensus is mixed with 42% buy ratings, but a $160.24 price target suggests caution relative to the current price. Institutional interest is growing, supporting momentum.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
